CD200R agonist (ARQ-234)


ARQ-234 is currently in preclinical development.

ARQ-234 is a fusion protein that serves as an agonist with high selectivity and potency for the CD200 receptor (CD200R).1

Atopic dermatitis 

CD200R in atopic dermatitis.

Clinical landscape

  • Atopic dermatitis is a common, chronic inflammatory skin disease affecting both children and adults2
  • Itch is the most burdensome symptom, causing patients to experience substantially reduced quality of life and sleep disturbances3
  • The skin barrier is typically compromised in atopic dermatitis4
  • Topical corticosteroids and emollients are the standard of care4
  • Steroids are not suitable for long-term use, and children are at risk of greater systemic absorption4

Proposed MOA

  • CD200R is expressed by cells involved in type 2 inflammation5
  • CD200R agonists activate the pathway that regulates immune cell activation1
  • ARQ-234 binds to CD200R, inducing inhibitory signaling on immune cells that regulate inflammation1

MOA = mechanism of action

Clinical programs


ARQ-234 is currently in preclinical development.


1. Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd. News release. Arcutis Biotherapeutics, Inc; September 7, 2022. 2. Bieber. Ann Dermatol. 2010;22:125-137. 3. Silverberg et al. Ann Allergy Asthma Immunol. 2018;121:340-347. 4. Nygaard et al. Dermatology. 2017;233:333-343. 5. Blom et al. Allergy. 2017;72:1081-1090.

Arcutis Biotherapeutics logo

This website is intended for US healthcare professionals only. There may be information included that pertains to an investigational therapy or formulation that has not yet been approved for use in your country. The safety and efficacy of investigational therapies and/or formulations and/or uses have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated. This information is as of 7/2024 to the best of the Company’s knowledge and Arcutis assumes no obligation to update this information.

© 2024 Arcutis Biotherapeutics, Inc. All rights reserved. MED-MULTI-2100006 v6.0 7/24